相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Derivatives of nitrogen mustard anticancer agents with improved cytotoxicity
Frauke Antoni et al.
ARCHIV DER PHARMAZIE (2021)
Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma
Paul G. Richardson et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
Francesca Bonello et al.
PHARMACEUTICALS (2021)
A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant
Massimo Martino et al.
ANNALS OF HEMATOLOGY (2020)
Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future
Benjamin Diamond et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2020)
The changing role of high dose melphalan with stem cell rescue in the treatment of newly diagnosed multiple myeloma in the era of modern therapies-back to the future!
Dickran Kazandjian et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2020)
Expression, mutation, and methylation of cereblon-pathway genes at pre- and post-lenalidomide treatment in multiple myeloma
Takuto Tachita et al.
CANCER SCIENCE (2020)
Multiple myeloma: Role of autologous transplantation
Ioannis Ntanasis-Stathopoulos et al.
CANCER TREATMENT REVIEWS (2020)
OCEAN: a randomized Phase III study of melflufen plus dexamethasone to treat relapsed refractory multiple myeloma
Fredrik Schjesvold et al.
FUTURE ONCOLOGY (2020)
Multiple Myeloma: Available Therapies and Causes of Drug Resistance
Vanessa Pinto et al.
CANCERS (2020)
Are Autologous Stem Cell Transplants Still Required to Treat Myeloma in the Era of Novel Therapies? A Review from the Chronic Malignancies Working Party of the EBMT
Laurent Garderet et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Chemical modification of melphalan as a key to improving treatment of haematological malignancies
Arkadiusz Gajek et al.
SCIENTIFIC REPORTS (2020)
Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study
Paul G. Richardson et al.
LANCET HAEMATOLOGY (2020)
The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift?
Dickran Kazandjian et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis
Vania Hungria et al.
ADVANCES IN THERAPY (2020)
Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant
Tarek H. Mouhieddine et al.
NATURE COMMUNICATIONS (2020)
Allogenic stem cell transplantation in multiple myeloma: dead or alive and kicking?
Massimo Martino et al.
PANMINERVA MEDICA (2020)
A case report: high dose melphalan as a conditioning regimen for multiple myeloma induces sinus arrest
Liang-Liang Ma et al.
CARDIO-ONCOLOGY (2020)
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
Brian A. Walker et al.
LEUKEMIA (2019)
Glucocorticoids in multiple myeloma: past, present, and future
Nicholas Burwick et al.
ANNALS OF HEMATOLOGY (2019)
Frontline treatment for transplant-eligible multiple myeloma: A 6474 patients network meta-analysis
Leo Sekine et al.
HEMATOLOGICAL ONCOLOGY (2019)
The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial
Gordon Cook et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Daratumumab: A Review in Combination Therapy for Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Yahiya Y. Syed
DRUGS (2019)
Cardiac Complications in the Adult Bone Marrow Transplant Patient
Mirela Tuzovic et al.
CURRENT ONCOLOGY REPORTS (2019)
Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial
Qaiser Bashir et al.
LANCET HAEMATOLOGY (2019)
Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells
Claire Gourzones et al.
CANCERS (2019)
Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial
Xavier Leleu et al.
CLINICAL CANCER RESEARCH (2019)
Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2018
Evangelos Terpos et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
T. Facon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Dose Adjustment Helps Obtain Better Outcomes in Multiple Myeloma Patients with Bortezomib, Melphalan, and Prednisolone (VMP) Treatment
Su-Hee Cho et al.
TURKISH JOURNAL OF HEMATOLOGY (2019)
Current status of autologous stem cell transplantation for multiple myeloma
Rama Al Hamed et al.
BLOOD CANCER JOURNAL (2019)
Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma
Katarina Uttervall et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2019)
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma
Laura Rosinol et al.
BLOOD (2019)
In-Hospital Complications and Outcomes of Autologous Stem Cell Transplantation in Multiple Myeloma Patients Older Than 65-Years Old in the United States: National Inpatient Sample Analysis, 2011-2015
Veli Bakalov et al.
BLOOD (2019)
Navigating the treatment landscape in multiple myeloma: which combinations to use and when?
Hartmut Goldschmidt et al.
ANNALS OF HEMATOLOGY (2019)
A Bispecific CAR-T Cell Therapy Targeting Bcma and CD38 for Relapsed/Refractory Multiple Myeloma: Updated Results from a Phase 1 Dose-Climbing Trial
Chenggong Li et al.
BLOOD (2019)
Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial
Edward A. Stadtmauer et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
Meletios A. Dimopoulos et al.
LANCET (2019)
Deregulation and Targeting of TP53 Pathway in Multiple Myeloma
Katarina K. Jovanovic et al.
FRONTIERS IN ONCOLOGY (2019)
Assessment of TP53 lesions for p53 system functionality and drug resistance in multiple myeloma using an isogenic cell line model
Umair Munawar et al.
SCIENTIFIC REPORTS (2019)
Stem-cell transplantation in multiple myeloma: how far have we come?
Cinnie Y. Soekojo et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2019)
Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party
Holger W. Auner et al.
HAEMATOLOGICA (2018)
Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time
S. K. Kumar et al.
LEUKEMIA (2018)
Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party
Holger W. Auner et al.
HAEMATOLOGICA (2018)
Engraftment Kinetics after High-Dose Melphalan Autologous Stem Cell Transplant in Patients with Multiple Myeloma
Lizamarie Bachier-Rodriguez et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Various Signaling Pathways in Multiple Myeloma Cells and Effects of Treatment on These Pathways
Ali Dehghanifard et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Water-soluble porphyrin-PAMAM-conjugates of melphalan and their anticancer activity
Julio Cesar Ramirez-Arroniz et al.
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY (2018)
Therapeutic journery of nitrogen mustard as alkylating anticancer agents: Historic to future perspectives
Rajesh K. Singh et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Insights into the Structure, Function, and Ligand Discovery of the Large Neutral Amino Acid Transporter 1, LAT1
Natesh Singh et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Proteasome inhibitors for multiple myeloma
Kiyoshi Okazuka et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2018)
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
M. -V. Mateos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Knockdown of Linc00515 Inhibits Multiple Myeloma Autophagy and Chemoresistance by Upregulating miR-140-5p and Downregulating ATG14
Daifeng Lu et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma
Laurent Garderet et al.
BLOOD (2018)
Venetoclax for the treatment of multiple myeloma
Iuliana Vaxman et al.
EXPERT REVIEW OF HEMATOLOGY (2018)
CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma
Fabio Morandi et al.
FRONTIERS IN IMMUNOLOGY (2018)
Palonosetron, aprepitant, and dexamethasone for prevention of nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: A phase II study
Atsushi Isoda et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2017)
Melphalan hydrochloride for the treatment of multiple myeloma
Fabrizio Esma et al.
EXPERT OPINION ON PHARMACOTHERAPY (2017)
Developments in the Field of Myeloma in the Last Decade
Tapan K. Saikia
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION (2017)
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
Meletios A. Dimopoulos et al.
LANCET ONCOLOGY (2017)
RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma
E. Viziteu et al.
LEUKEMIA (2017)
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Developments in the Field of Myeloma in the Last Decade
Tapan K. Saikia
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION (2017)
Melflufen - a peptidase-potentiated alkylating agent in clinical trials
Malin Wickstrom et al.
ONCOTARGET (2017)
Management of multiple myeloma in the newly diagnosed patient
Maria-Victoria Mateosi et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2017)
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma
Shaji Kumar et al.
BLOOD (2017)
In-Hospital Mortality and Post-Transplantation Complications in Elderly Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Population-Based Study
Larysa Sanchez et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells
Annamaria Gulla et al.
CLINICAL CANCER RESEARCH (2016)
Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma
Bernard Maybury et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
Niels Weinhold et al.
BLOOD (2016)
In vitro and in vivo activity of melflufen (J1)in lymphoma
Maryam Delforoush et al.
BMC CANCER (2016)
Immunostimulatory Effects of Melphalan and Usefulness in Adoptive Cell Therapy with Antitumor CD4+T Cells
Michal Kuczma et al.
CRITICAL REVIEWS IN IMMUNOLOGY (2016)
Melphalan-flufenamide is cytotoxic and potentiates treatment with chemotherapy and the Src inhibitor dasatinib in urothelial carcinoma
Kristina Viktorsson et al.
MOLECULAR ONCOLOGY (2016)
Highly Expressed Integrin-α8 Induces Epithelial to Mesenchymal Transition-Like Features in Multiple Myeloma with Early Relapse
Jiyeon Ryu et al.
MOLECULES AND CELLS (2016)
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Preclinical activity of melflufen (J1) in ovarian cancer
Charlotte Carlier et al.
ONCOTARGET (2016)
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial
Gordon Cook et al.
LANCET HAEMATOLOGY (2016)
Synthesis and in vitro evaluation of a hyaluronic acid-quantum dots-melphalan conjugate
Haixing Xu et al.
CARBOHYDRATE POLYMERS (2015)
Bendamustine in multiple myeloma
Massimo Gentile et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2015)
First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies
Ake Berglund et al.
INVESTIGATIONAL NEW DRUGS (2015)
Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine
George Mattheolabakis et al.
JOURNAL OF DRUG TARGETING (2015)
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial
Francesca Gay et al.
LANCET ONCOLOGY (2015)
The role of P-glycoprotein in drug resistance in multiple myeloma
Joseph Abraham et al.
LEUKEMIA & LYMPHOMA (2015)
Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents
M. Merz et al.
ANNALS OF ONCOLOGY (2014)
Not too little, not too much-just right! (Better ways to give high dose melphalan)
P. J. Shaw et al.
BONE MARROW TRANSPLANTATION (2014)
A novel melphalan polymeric prodrug: Preparation and property study
Dan Li et al.
CARBOHYDRATE POLYMERS (2014)
Autologous Transplantation and Maintenance Therapy in Multiple Myeloma
A. Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Gang Lu et al.
SCIENCE (2014)
The novel alkylating prodrug melflufen (J1) inhibits angiogenesis in vitro and in vivo
Sara Strese et al.
BIOCHEMICAL PHARMACOLOGY (2013)
Preparation, characterization, and in vitro efficacy of O-carboxymethyl chitosan conjugate of melphalan
Bo Lu et al.
CARBOHYDRATE POLYMERS (2013)
In Vitro and In Vivo Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells
Dharminder Chauhan et al.
CLINICAL CANCER RESEARCH (2013)
An Inverse Switch in DNA Base Excision and Strand Break Repair Contributes to Melphalan Resistance in Multiple Myeloma Cells
Mirta M. L. Sousa et al.
PLOS ONE (2013)
Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms
Jahangir Abdi et al.
ONCOTARGET (2013)
Overexpression of MDR1 and survivin, and decreased Bim expression mediate multidrug-resistance in multiple myeloma cells
Masanobu Tsubaki et al.
LEUKEMIA RESEARCH (2012)
Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion
Paola Neri et al.
BLOOD (2011)
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation
Michele Cavo et al.
BLOOD (2011)
Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma
Sally A. Hunsucker et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Melphalan-Prednisolone and Vincristine-Doxorubicin-Dexamethasone Chemotherapy followed by Prednisolone/Interferon Maintenance Therapy for Multiple Myeloma: Japan Clinical Oncology Group Study, JCOG0112
Takaaki Chou et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2011)
Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan
C. Dumontet et al.
BONE MARROW TRANSPLANTATION (2010)
Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study
Juan Jose Lahuerta et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
H. Quach et al.
LEUKEMIA (2010)
Epigenetics of multiple myeloma after treatment with cytostatics and gamma radiation
Jana Krejci et al.
LEUKEMIA RESEARCH (2009)
Population Pharmacokinetics of Melphalan and Glutathione S-transferase Polymorphisms in Relation to Side Effects (vol 83, pg 749, 2008)
A. Kuehne et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Population pharmacokinetics of melphalan and glutathione S-transferase polymorphisms in relation to side effects
A. Kuehne et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Histone deacetylase inhibitors: molecular mechanisms of action
W. S. Xu et al.
ONCOGENE (2007)
Melphalan and its role in the management of patients with multiple myeloma
Patrizia Falco et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2007)
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome
Herve Avet-Loiseau et al.
BLOOD (2007)
Polymorphisms in the genes ERCC2, XRCC3 and CD3EAP influence treatment outcome in multiple myeloma patients undergoing autologous bone marrow transplantation
Annette Vangsted et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis
HJ Yan et al.
CANCER RESEARCH (2006)
Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma:: results of a pilot study including biological aspects
JF Rossi et al.
BONE MARROW TRANSPLANTATION (2005)
Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation
A Spencer et al.
BONE MARROW TRANSPLANTATION (2005)
Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies
P Mougenot et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
L-type amino acid transporter-1 overexpression and melphalan sensitivity in Barrett's adenocarcinoma
J Lin et al.
NEOPLASIA (2004)
Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells
D Chauhan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
分享论文
